# US 2019/0314301 A1 · Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314301 A1
- Document ID: US20190314301A1
- Status: Published application
- Kind: A1
- Application number: 16/317,009
- Filed: 2017-07-13
- Published: 2019-10-17
- Earliest claimed: 2016-07-13
- Assignees: Atrogi AB
- Applicants: Atrogi AB
- Inventors: Benjamin PELCMAN; Tore BENGTSSON
- Web page: https://patentgrep.com/patent/US20190314301A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/426: 1,3-Thiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is herein provided pharmaceutical formulations and kits-of-parts comprising a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a β3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.

## Claims

### Claim 1

A pharmaceutical formulation comprising:
(a) a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof; and
(b) a β3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is selected from the group consisting of formoterol, arformoterol, salmeterol, (R)-salmeterol, vilanterol, zilpaterol, clenbuterol, (R)-clenbuterol, bitolterol, salbutamol, levosalbutamol, terbutaline, metaproterenol, pirbuterol, bambuterol, fenoterol, methoxyfenoterol, isoprenaline, procaterol, ritodrine, indacaterol, olodaterol, colterol, hexaprenaline, carmoterol, isoxsuprine, isoetarine, zinterol, bamethane, clencyclohexerol, tulobuterol, BRL-47672, trantinterol, clenproperol, clenpenterol, brombuterol, ractopamine and abediterol, and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is selected from the group consisting of formoterol, arformoterol, salmeterol, (R)-salmeterol, vilanterol, zilpaterol, clenbuterol, (R)-clenbuterol, indacaterol, olodaterol, carmoterol, bamethane, clencyclohexerol, tulobuterol, trantinterol and abediterol, and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is selected from the group consisting of formoterol, arformoterol, salmeterol, (R)-salmeterol, clenbuterol, (R)-clenbuterol, bamethane, trantinterol and abediterol, and pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is a long-acting β2-adrenergic receptor agonist or an ultra-long-acting β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is clenbuterol, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β3-adrenergic receptor agonist is selected from the group consisting of BRL-37344, BRL-35135, mirabegron, amirabegron, SR59104A, SR59119A, solabegron, vibegron, CAS: 1269433-49-9, CAS: 1269433-05-7, MK-0634, ritobegron, BMS-187257, CL 316,243, CGP 12177, L-755,507, L-742,791, L-750,355, L-749,372, SB-226552, SB-251023, ICI-D 7114, FR 149175, Ro40-2148, CAS: 769118-12-9, rafabegron, BMS-196085, trecadrine, SB-418790 and CAS: 99151-51-6, and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β3-adrenergic receptor agonist is selected from the group consisting of BRL-37344, BRL-35135, mirabegron, amirabegron, solabegron, vibegron, CAS: 1269433-49-9, CAS: 1269433-05-7 and ritobegron, and pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β3-adrenergic receptor agonist is selected from the group consisting of mirabegron, vibegron, CAS: 1269433-49-9 and CAS: 1269433-05-7, and pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β3-adrenergic receptor agonist is mirabegron, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the β2-adrenergic receptor agonist is clenbuterol, or a pharmaceutically acceptable salt thereof, and the β3-adrenergic receptor agonist is mirabegron, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A kit-of-parts comprising components:
(A) a pharmaceutical formulation comprising a β2-adrenergic receptor agonist as defined in claim 1, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable excipient; and
(B) a pharmaceutical formulation comprising a β3-adrenergic receptor agonist as defined in claim 1, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable excipient,
which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

### Claim 13 (depends on 12)

A kit-of-parts comprising:
(I) one of components (A) or (B) as defined in claim 12; and
(II) instructions to use that component in conjunction with the other of the two components.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 1)

A method of treating type 2 diabetes, which method comprises administering a therapeutically effective amount of the pharmaceutical formulation as claimed in claim 1 to a patient in need of such treatment.

### Claim 17 (depends on 1)

A method of treating type 2 diabetes, which method comprises the administration of a therapeutically effective amount of a β2-adrenergic receptor agonist as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a β3-adrenergic receptor agonist as defined in claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

### Claim at position 17

18-21. (canceled)
